The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Starting as early as 2006 with an analysis from Hong Kong, an overall 21 reports of HILI cases were published which had been assessed for causality using RUCAM with results presented by groups with first authors having their working place in mainland China, Hong Kong, or Taiwan.
“Starting as early as 2006 with an analysis from Hong Kong,18 an overall 21 reports of HILI cases were published which had been assessed for causality using RUCAM with results presented by groups with first authors having their working place in mainland China, Hong Kong, or Taiwan.18–38”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [25]
Gao et al. used RUCAM for the first time in hepatic sinusoidal obstruction syndrome caused by PAs in 23 patients, supporting blood pyrrole-protein adducts as diagnostic biomarkers.
“as shown in their report assessing causality by Gao et al.,25 RUCAM was used for the first time in the hepatic sinusoidal obstruction syndrome caused by PAs in 23 patients, supporting the blood pyrrole-protein adducts as diagnostic biomarkers.25”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [25]
Some studies included HILI cases not only with highly probable or probable causality gradings but also with a possible causality level based on RUCAM scores ≥3.
“Some studies included HILI cases not only with highly probable or probable causality gradings but also with a possible causality level based on RUCAM scores ≥3 (Table 1).24,25,27,28,30,36,38”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [25]
There is now increasing awareness of the benefits provided by RUCAM among various countries, including China, Korea, and Singapore, as evidenced by reports initially published in 2004 from Korea and in 2006 from China and Singapore, with subsequent articles.
“There is now increasing awareness of the benefits provided by RUCAM among various countries, including China,18–38 Korea,40–54 and Singapore,55,56 as evidenced by reports initially published in 2004 from Korea40 and in 2006 from China18 and Singapore,55 with subsequent articles (Table 1).”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [25]
On top among the Asian countries is currently China, best explained by the large population and heavy use of herbal traditional Chinese medicines, with increasing numbers of publications and cases until 2019.
“On top among the Asian countries is currently China, best explained by the large population and heavy use of herbal traditional Chinese medicines (TCMs), with increasing numbers of publications and cases until 2019.18–38”
From Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases (2020) · cites this paper as [25]
Pyrrole protein adducts detected in the patient's blood have a retrospective significance for diagnosis of PA-HSOS.
“Pyrrole protein adducts detected in the patient's blood have a retrospective significance for diagnosis [91].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418
Flagged first, then by citations
Research works printed but not linked: 17
- [2]Teschke R Frenzel C Glass X Schulze J Eickhoff A Herbal hepatotoxicity: a critical review Br J Clin Pharmacol 2013 75 3 630 636 22831551 PMC3575930
- [3]Wang JY Gao H Tusanqi and hepatic sinusoidal obstruction syndrome J Dig Dis 2014 15 3 105 107 24528632
- [4]Wadleigh M Ho V Momtaz P Richardson P Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment Curr Opin Hematol 2003 10 6 451 462 14564177
- [5]Helmy A Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome Aliment Pharmacol Ther 2006 23 1 11 25 16393276
- [6]Chen Z Huo JR Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations Neth J Med 2010 68 6 252 260 20558855
- [7]Dübecke A Beckh G Lüllmann C Pyrrolizidine alkaloids in honey and bee pollen Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2011 28 3 348 358 21360377
- [8]Chojkier M Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids J Hepatol 2003 39 3 437 446 12927933
- [9]Edgar JA Colegate SM Boppré M Molyneux RJ Pyrrolizidine alkaloids in food: a spectrum of potential health consequences Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2011 28 3 308 324 21360376
- [10]Fu PP Xia Q Lin G Chou MW Pyrrolizidine alkaloids – genotoxicity, metabolism enzymes, metabolic activation, and mechanisms Drug Metab Rev 2004 36 1 1 55 15072438
- [11]Lin G Wang JY Li N Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum J Hepatol 2011 54 4 666 673 21146894
- [12]Gao H Li N Wang JY Zhang SC Lin G Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids J Dig Dis 2012 13 1 33 39 22188914
- [13]Chalasani NP Hayashi PH Bonkovsky HL Navarro VJ Lee WM Fontana RJ Practice Parameters Committee of the American College of Gastroenterology ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury Am J Gastroenterol 2014 109 7 950 966 24935270
- [14]Lin G Cui YY Hawes EM Microsomal formation of a pyrrolic alcohol glutathione conjugate of clivorine. Firm evidence for the formation of a pyrrolic metabolite of an otonecine-type pyrrolizidine alkaloid Drug Metab Dispos 1998 26 2 181 184 9456306
- [15]Bearman SI Anderson GL Mori M Hinds MS Shulman HM McDonald GB Venoocclusive disease of liver: development of a model for predicting fatal outcome after marrow transplantation J Clin Oncol 1993 11 9 1729 1736 8355040
- [16]McDonald GB Hinds MS Fisher LD Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118 4 255 267 8420443
- [17]Bunchorntavakul C Reddy KR Review article: herbal and dietary supplement hepatotoxicity Aliment Pharmacol Ther 2013 37 1 3 17 23121117
- [18]Teschke R Wolff A Frenzel C Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment World J Hepatol 2014 6 1 17 32 24653791 PMC3953808
Cited by
Sorted by citations
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Self-citationTeschke, R., Zhu, Y., & Jing, J. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00009 · Cited by 41
Metadata
- Authors
- Gao, H., Ruan, J.-Q., Chen, J., Li, N., Ke, C.-Q., Ye, Y., Lin, G., & Wang, J.-Y.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-08
- Pages
- 4861
- ISSN
- 1177-8881
- PMC
- PMC4554430
- Cited by
- 58
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
